Search

Objective: Determine the prevalence of Vancomycin-resistant enterococci (VRE) colonizing the intestinal tract of hospitalized patients and define risk factors., Material and Methods: A point prevalence survey of VRE fecal carriage was carried out among patients who stayed at a 600-bed teaching hospital for at least two days. Resistance to vancomycin was detected by the E-test method. Epidemiological data was recorded for all patients included in the study and was used for the risk factor analysis., Results: A total of 128 patients hospitalized for at least two days were enrolled in this investigation. Thirty-nine patients (30.5%) were colonized with vancomycin-resistant enterococci. Twenty-three of the 39 strains were identified as Enterococcus faecium, 13 were identified as Enterococcus gallinarum and three strains as Enterococcus casseliflavus. The risk factors that were significantly associated with VRE colonization included length of hospital stay (13.2 days vs. 8.6 days), age (60.7 years vs. 47.7 years) and the presence of underlying malignancies (28.2% vs. 11.2%). An association was found between VRE colonization and the use of antimicrobials with anaerobic activity, such as metronidazole, piperacillin/tazobactam and imipenem. The use of vancomycin was associated with VRE colonization in the intensive care unit., Conclusions: VRE colonization must be monitored, and risk factors should be determined, because they are useful for screening hospitalized patients for VRE colonization in order to establish prevention and control measures.

Staphylococcus aureus strains resistant to a variety of antimicrobial agents are often found in the hospital environment and are responsible for many life-threatening infections. The activity of quinupristin/dalfopristin against 84 Staphylococcus aureus bloodstream isolates (both methicillin resistant and methicillin sensitive) was compared to the activity of vancomycin, teicoplanin, erythromycin, oxacillin, clindamycin, gentamicin, rifampicin. The Minimum Inhibitory Concentrations of these agents was evaluated with the Epsilometer Test. Quinupristin/dalfopristin inhibited all methicillin-sensitive strains at 1mg/L, and 75% of methicillin-resistant strains at 1.5mg/L. According to these results, quinupristin-dalfopristin shows promising in-vitro activity and may be a welcome alternative treatment for methicillin-resistant staphylococcal infections, resulting in reduced use of glycopeptides.